Experimental cell therapy takes on lupus in early trial
NCT ID NCT07314567
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a new treatment called ACE1831 for people with lupus that has not responded to standard therapies. ACE1831 is made from healthy donor immune cells and is given after a short course of chemotherapy. The study will enroll 22 adults aged 18 to 60 with moderate to severe active lupus to see if the treatment is safe and shows signs of helping control the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ACE1831 (a type of immune cell therapy made from healthy donors' cells, given with chemotherapy)
What this could lead to
If this works, it could point toward a new treatment option for people with lupus that hasn't responded to other therapies.
What could go wrong
This is a very early, small study with only 22 participants, so results may not apply to everyone. The treatment involves chemotherapy and carries risks like infections or side effects from the cell infusion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEM LUPUS ERYTHEMATOSUS(SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tongji Hospital
Wuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••